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Submitted Jan 28, 2014; accepted Apr 6, 2014.DISCUSSIONDr Jeffery B. Dattilo (Nashville, Tenn). Dr Bercelli, Dr
Endean, members of the program committee; I wish to express
my gratitude for being asked to review this manuscript from our
colleagues from Eastern Virginia. The manuscript is well written
and I appreciate the communication regarding the report before
the meeting, giving me ample time for review.
Clearly this is a controversial topic, as the remaining member-
ship present on this beautiful Saturday, will undoubtedly agree.
Historically, as the authors admit, nonsurgical aggressive medical
management was and still remains the mainstay of treatment for
these descending aortic conditions. The modern literature, howev-
er, suggests that endoluminal repair of these pathologies is gaining
momentum primarily because of the initial technical success rate
and fewer comorbid consequences of open surgical therapy. Thisoften requires more coverage of the descending aorta because
the nidus of the injury cannot always be readily identiﬁed and
thus subjecting the patient to dreaded complications such as
paraplegiadwhich was not inconsequentialdin your cohort of
patients.
I have a couple of questions.
Your group had, on average, seven patients per year that you
treated with endoluminal therapy. Do you have the numbers of the
patients you treated with traditional medical management of pain
control and aggressive blood pressure control? I ask because the
number of treated patients seems somewhat high for a single
institution.
You intimated that there would be follow-up computed to-
mography (CT) scans performed during the initial hospitalization.
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sion? What if you don’t treat endoluminallydwhen do you see
these patients back in clinic?
Because intractable pain was one of your primary end points
compelling you to intervene and this can be enormously
subjectiveddo you have standardized pain control protocols? Do
you involve pain management teams at your institution?
I look forward to your answers and ﬁnally, Dr Lavingia, I wish
you every bit of good fortune in your quest for publication of this
manuscript. I appreciate the opportunity to discuss this issue
among the membership.
Dr Kedar S. Lavingia. First of all, I would like to thank you
for your kind comments and questions. Addressing your ﬁrst ques-
tion about patients treated with medical therapy, we are currently
working on identifying patients who did not receive endovascular
intervention and, unfortunately, cannot provide that information
right now. The difﬁculty in establishing that cohort is that there
is no speciﬁc International Classiﬁcation of Diseases-Ninth Revi-
sion code for intramural hematoma and these patients need to
be separated from a larger cohort of patients with an International
Classiﬁcation of Diseases-Ninth Revision code of thoracic or thor-
acoabdominal aortic dissection. At our institution, we seeapproximately two acute aortic syndrome cases a week, so there
is a signiﬁcant group of patients being treated with medical
management.
In regard to your second question on follow-up imaging, we
do have protocols in place. All patients who are admitted for
intramural hematoma undergo CT imaging on admission and
before discharge with follow-up in our ofﬁce in 1 to 3 months
after discharge. They also receive imaging at six months and at
one year and yearly thereafter. When we observe aortic remod-
eling, the imaging interval is increased to 2 to 3 years. All pa-
tients treated with TEVAR underwent a similar CT imaging
protocol.
As far as your third question regarding pain control, all pa-
tients were initially managed with intravenous morphine or dilau-
did and subsequently transitioned to patient-controlled analgesia if
they were going to be in the hospital for extended periods of time.
We typically do not involve our pain management teams but have
most success managing these patients’ pain with aggressive blood
pressure control. In our series, most patients had objective indica-
tions to intervene such as rupture or progression to dissection
whereas intractable pain alone was an uncommon surgical
indication.
